You are here:
Direct Healthcare Professional Communication (DHPC) on metamizole: risk of drug-induced liver injury
2020.12.15
Active substance: metamizole
The marketing authorisation holders of metamizole-containing medicinal products in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that cases of drug-induced liver injury (DILI) with metamizole have been reported.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN